# Ophelia Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ophelia-health

- Industry: Healthcare Specialists
- Headquarters: New York, US
- Website: www.meetophelia.com
- Total disclosed funding: $68M
- Latest round: Series B (Dec 9, 2021)
- Investors on record: 14

## About

Ophelia Health, Inc. is a telehealth provider specializing in accessible treatment for opioid use disorder, utilizing digital platforms to connect patients with licensed clinicians for effective management through Suboxone® prescriptions.Ophelia Health, Inc. provides telehealth services to treat opioid use disorder. The company was founded by Elliot Barbernell and Zack Gray. Its headquarters is located in New York, US. The latest funding round was a Series B on December 9, 2021, raising USD 50.00 mn led by Tiger Global Management, with participation from other investors including 640 Oxford Ventures and General Catalyst Partners. Ophelia has raised a total of USD 50.00 mn, and its current company valuation is USD 246.36 mn.Ophelia offers telehealth services focused on the treatment of opioid use disorder, primarily through the prescription of Suboxone® (buprenorphine and naloxone). Patients connect with licensed clinicians via Zoom for consultations and prescriptions, providing necessary support for those managing opioid dependence. The service caters to a diverse clientele, including those on Medicaid and private insurance, with minimal out-of-pocket costs, typically less than USD 10 a month. Ophelia operates across various states in the United States, addressing a critical need for accessible addiction treatment.Ophelia’s revenue model is subscription-based, covering clinician visits, Suboxone management, and ongoing support from care teams. The company collaborates with many health insurers, including Medicaid, to expand its market reach. Most patients incur low monthly fees around USD 10 for comprehensive telehealth services, enabling consistent client transactions and access to essential care without significant financial burden. Suboxone is central to its offerings, facilitating a medically supervised approach to opioid dependence management.Following the Series B funding round in December 2021, which raised USD 50.00 mn, Ophelia Health, Inc. plans to expand its treatment programs to serve more patients and clinicians throughout the United States. The funding will also support integration with additional payors and partners and enhance the recruitment, training, and support platform for clinicians. Ophelia aims to increase its geographic footprint and patient reach significantly in the upcoming years.

## Funding rounds

- Series B, Dec 9, 2021, $50M — Menlo Ventures, General Catalyst Partners, Tiger Global Management, Interplay, Refactor Capital, 640 Oxford Ventures, Good Friends
- Series A, Apr 5, 2021, $15M — Menlo Ventures, General Catalyst Partners, Y Combinator, Warby Parker Inc., Flatiron Health, Inc., PillPack LLC, Allbirds, Inc., Refactor Capital, Carbon Health, Bloom Institute of Technology
- Seed, Apr 23, 2020, $3.4M — General Catalyst Partners, Y Combinator, Refactor Capital

## Investors

- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Seed, Series A, Series B
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Seed, Series A
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed, Series A, Series B
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A, Series B
- Warby Parker Inc. — Series A
- Flatiron Health, Inc. — Series A
- PillPack LLC — Series A
- Allbirds, Inc. — Series A
- Carbon Health — Series A
- Bloom Institute of Technology — Series A
- Tiger Global Management (https://capitalatlas.ai/funds/tiger-global-management) — Series B
- Interplay (https://capitalatlas.ai/funds/interplay) — Series B
- 640 Oxford Ventures (https://capitalatlas.ai/funds/640-oxford-ventures) — Series B
- Good Friends — Series B